Navigation Links
Ambit Biosciences Completes $50 Million Financing to Advance Lead Drug Candidate in Acute Myeloid Leukemia
Date:11/6/2012

SAN DIEGO, Nov. 6, 2012 /PRNewswire/ -- Ambit Biosciences Inc. today announced that the company has closed the first $25 million tranche of a new $50 million preferred stock financing to support continued advancement of its lead drug candidate, quizartinib.  Existing investor OrbiMed Advisors led the financing with participation from other existing Ambit investors including Aisling Capital, Apposite Healthcare, Roche Ventures, GrowthWorks, MedImmune Ventures, Forward Ventures, GIMV, and Radius Ventures. 

"2012 has been a pivotal year of progress for Ambit, and this financing is a reflection of that progress and the momentum we have built as a team," said Michael Martino, President and CEO of Ambit. "We've received the data from our large, 333 patient Phase 2 trial of quizartinib in patients with relapsed/refractory AML, and we are excited to present that data at ASH in Atlanta in December. We've refocused and prioritized our work on earlier stage pipeline assets, including our oral JAK2 and CSF1R inhibitor programs, and re-energized the team. This financing, with OrbiMed Advisors leading a round in which all existing investors participated, is a strong vote of confidence in our direction and provides the resources to accelerate our progress in 2013.""  

In conjunction with the financing, David Bonita, M.D, of OrbiMed Advisors will join Ambit's board of directors.

"Ambit's new management team has impressed us with its focus on moving the company's core clinical programs forward in clinical development," said Dr. Bonita. "We believe that the recent data from its 333 patient Phase 2 trial in relapsed and refractory acute myeloid leukemia are very promising and look forward to working with the management team and their clinical collaborators in moving quizartinib through clinical development and into clinical use by physicians."

About Ambit Biosciences
Ambit Biosciences is a privately held biopharmaceutical compa
'/>"/>

SOURCE Ambit Biosciences Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
2. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
3. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
4. Amarantus BioSciences to Present at the New York Biotechnology Association (NYBA) 21st Annual Meeting on May 2nd, 2012
5. Neurocrine Biosciences Reports First Quarter 2012 Results
6. Pressure BioSciences, Inc. to Discuss First Quarter 2012 Financial Results And Provide Business Update
7. Neurocrine Biosciences to Present at the Jefferies 2012 Global Healthcare Conference
8. 3-V Biosciences To Present at the Seventh Annual JMP Securities Healthcare Conference
9. Sofie Biosciences receives $1M Phase II SBIR grant from the DOE
10. Frost & Sullivan 2012 New Product Innovation in Bioanalytics Awarded to Protea Biosciences
11. Pressure BioSciences Patented PCT Platform Shown to Significantly Improve Protein and DNA Detection in Multiple Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... , Aug. 21, 2014 /CNW/ - Bedrocan Cannabis Corp., ... independent members to its Board of Directors, enhancing ... of the company, a leading licensed producer of ... Internationally, Bedrocan has 13 years, experience in producing ... seven countries, including Canada. As ...
(Date:8/21/2014)... Aug. 21, 2014   Auxilium Pharmaceuticals, Inc. ... biopharmaceutical company, today announced positive results from a ... histolyticum (or CCH) for the treatment of edematous ... the Phase 2a trial, all three doses of ... showed an improvement in the appearance of cellulite ...
(Date:8/20/2014)... , Aug. 20, 2014  The National Association ... latest results achieved by the real-time, pseudoephedrine (PSE) ... National Precursor Log Exchange (NPLEx), automatically blocks unlawful ... down methamphetamine offenders and make arrests. Data released ... Missouri blocked the sale of more ...
Breaking Medicine Technology:Senior Life Sciences Executives Join Bedrocan as Independent Directors 2Senior Life Sciences Executives Join Bedrocan as Independent Directors 3Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 2Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 3Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 4Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 5Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 6Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 7Missouri's Stop-Sale System Achieves Significant Results In Battle Against Meth 2
... ZURICH, July 16 An innovative ... fibrosis patients has received a second,orphan drug designation ... designation was,granted. The recent designation relates to Burkholderia ... fibrosis patients. For Axentis,Pharma AG of Zurich, Switzerland, ...
... , , , ... are a source of worry for many who fear Alzheimer,s ... July 16 issue of the New England Journal of Medicine suggests that ... to have memory declines in their mid-50s, far earlier than previously thought. ...
Cached Medicine Technology:Cystic Fibrosis - Liposomal Tobramycin Receives Second Orphan Drug Designation Within Weeks 2Cystic Fibrosis - Liposomal Tobramycin Receives Second Orphan Drug Designation Within Weeks 3Mayo Clinic Study Finds Earliest Evidence of Memory Decline in Middle-Aged People at Genetic Risk for Alzheimer's Disease 2Mayo Clinic Study Finds Earliest Evidence of Memory Decline in Middle-Aged People at Genetic Risk for Alzheimer's Disease 3Mayo Clinic Study Finds Earliest Evidence of Memory Decline in Middle-Aged People at Genetic Risk for Alzheimer's Disease 4Mayo Clinic Study Finds Earliest Evidence of Memory Decline in Middle-Aged People at Genetic Risk for Alzheimer's Disease 5Mayo Clinic Study Finds Earliest Evidence of Memory Decline in Middle-Aged People at Genetic Risk for Alzheimer's Disease 6Mayo Clinic Study Finds Earliest Evidence of Memory Decline in Middle-Aged People at Genetic Risk for Alzheimer's Disease 7
(Date:8/21/2014)... 21, 2014 When children go back to ... can cause them to become sick and risk missing school. ... to help them fight these germs to ensure a successful ... do just that with its XFactor program. , The XFactor ... chewable multi-vitamins. Children ages 4 and up can receive 30-day ...
(Date:8/21/2014)... 2014 Young girls with an intense, red, itchy ... increased risk of developing urinary tract infections (UTIs), according ... The treatment may be as simple as better hygiene ... swimming pools. , "Vulvitis is a common condition affecting ... Steve J. Hodges, M.D., associate professor of urology at ...
(Date:8/21/2014)... 21, 2014 Greater awareness among parents ... babies before they are full term has decreased the ... of the country, early elective deliveries (EEDs) still occur ... years, EED is defined as delivery before 39 weeks ... neonatal morbidity and mortality, and offers no benefit to ...
(Date:8/21/2014)... Steven Reinberg HealthDay ... An experimental drug shows promise in treating respiratory syncytial virus ... "We are finally making major progress in being able ... cause of serious viral pneumonia, second only to influenza virus," ... at the University of Tennessee College of Medicine in Memphis. ...
(Date:8/21/2014)... Indiana (PRWEB) August 21, 2014 ... employee benefits advisory organization, is pleased to announce ... Based in Knoxville, Tennessee, Trinity Benefit Advisors ... close, long-term relationships with their clients. Their consultative ... planning and objective setting, implementation, and monitoring. Their ...
Breaking Medicine News(10 mins):Health News:MedX Pharmacy Helps with Back to School Preparation 2Health News:Researchers identify potential risk factors for urinary tract infections in young girls 2Health News:New “Playbook” Aims to Eliminate Early Elective Deliveries in the United States 2Health News:New “Playbook” Aims to Eliminate Early Elective Deliveries in the United States 3Health News:New Drug May Fight Serious Respiratory Virus in Infants 2Health News:New Drug May Fight Serious Respiratory Virus in Infants 3Health News:Trinity Benefit Advisors is the Latest Firm to Join United Benefit Advisors 2Health News:Trinity Benefit Advisors is the Latest Firm to Join United Benefit Advisors 3
... The British Association for Psychopharmacology (BAP) has released fresh ... and addiction in the Journal of Psychopharmacology , ... researched the new, comprehensive guidelines, offering practitioners a detailed ... clinical decisions. The new BAP guidelines target treatment ...
... with intact proteins of the same kind, thereby triggering ... discovered by researchers from the RUB Heart and Diabetes ... Hendrik Milting in an interdisciplinary research project with colleagues ... report in the Journal of Biological Chemistry . ...
... , WEDNESDAY, May 23 (HealthDay News) -- The ... reduced through a multi-pronged approach that includes more training ... to a new German study. Despite legal regulations ... as bed rails and belts still are frequently used ...
... resilient metal wire designed to gather and compress diseased lung ... a subtype of the disease that involves specific, usually isolated ... multicenter international trial conducted in the Netherlands, Germany and France. ... be easily implanted and is designed to take the place ...
... imaging (MRI) provides an indication of a breast tumor,s ... clinical examination, according to a new study published online ... with breast cancer often undergo chemotherapy prior to surgery. ... known as neoadjuvant chemotherapy, are more likely to achieve ...
... Ill. -- Children born with cleft lip, cleft palate ... appearance. Patients can face serious airway, feeding, speech ... challenges, Laura Swibel Rosenthal, MD, of Loyola University Medical ... of Otolaryngologic Clinics of North America . ...
Cached Medicine News:Health News:British experts update addiction treatment guidelines 2Health News:Aggregating instead of stabilizing: New insights into the mechanisms of heart disease 2Health News:Study Offers Ways to Decrease Use of Restraints at Nursing Homes 2Health News:Tiny implanted coil improves lung function in patients with severe emphysema 2Health News:Tiny implanted coil improves lung function in patients with severe emphysema 3Health News:Breast MRI helps predict chemotherapy's effectiveness 2Health News:Cleft lip/palate cause much more than cosmetic problems 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: